Cath Lab Digest - November 2007 - (Page 14)

14 SPOTLIGHT NOVEMBER 2007 12 current enrolling trials in collaboration with 6 main investigators: Dr. Mayra Guerrero, Dr. Abdulrahman Arabi, Dr. Aaron Kugelmass, Dr. Henry Kim, Dr. Adam Greenbaum and Dr. Michael Hudson. We are currently participating in the following clinical trials: Enrolling: • TRACER. A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 (a thrombin inhibitor) in addition to standard of care in acute coronary syndrome (ACS). Primary Investigator: Henry Kim, MD • ERASE. Early Rapid Reversal of platelet thrombosis with IV PRT060128 (an anti-platelet) before percutaneous coronary intervention (PCI) to optimize reperfusion in acute myocardial infarction (AMI). Principal Investigator: Adam Greenbaum, MD • EVENT REGISTRY. A multi-center registry for the evaluation of drug-eluting stents and ischemic events. Primary Investigator: Adam Greenbaum, MD • ENDOPAT: ACEDE. Assessment of chest pain in the emergency department using Endo-PAT (Peripheral Arterial Tonometry). EndoPAT is a diagnostic device for assessing coronary artery disease (CAD) risk through endothelial function testing, using PAT combined with reactive hyperemia. Primary Investigator: James Mccord, MD • CHAMPION PLATFORM. A clinical trial comparing treatment with Cangrelor, an IV anti-platelet agent, (in combination with usual care), to usual care, in subjects who require percutaneous intervention. Primary Investigator: Adam Greenbaum, MD • CHAMPION PCI. A clinical trial comparing treatment with Cangrelor (an IV antiplatelet agent) to clopidogrel in subjects who require percutaneous intervention. Primary Investigator: Adam Greenbaum, MD • REVEAL: Erythropoietin for AMI NIH. Randomized, multi-center, double-blind, and placebo-controlled trial of the effects of erythropoietin on infarct size and left ventricular remodeling in survivors of acute myocardial infarction. The primary objective of this study is to determine whether erythropoietin administration affects infarct size, left ventricular remodeling and circulating endothelial progenitor cells in patients with large MIs. The size of the infarction and the dimensions of the heart will be assessed by cardiac magnetic resonance imaging within 2-6 days of the infusion and again approximately 3 months later. Primary Investigator: Adam Greenbaum, MD Left to right: Aaron Kugelmass MD, Director, Cardiac Cath Lab, Associate Chief, Cardiovascular Medicine, Claudio Schuger MD, Director, Electrophysiology Laboratory. EP/Cath Lab Assistant Managers: Edward Muxlow RN, Patti Renaud RN BSN marked, measured, timed and dated for further evaluation. Cardiac fellows are responsible for seeing inpatients at the end of each day to evaluate vascular access sites and monitor patients for potential post catheterization complications. How is inventory managed at your cath lab? Who handles the purchasing of equipment and supplies? We have one expert materials management coordinator that is responsible for all coronary, peripheral and EP inventory. Kelly Campau oversees over 10,000 products and over 4 million dollars in inventory. Ninety percent of our inventory is purchased via consignment contracts. Our software system is Cardio.Connect (Alinium, Austin, TX), which assists in managing overstock and consignment contracts. Utilizing a bar code system with pre determined par levels, items are scanned per case and uploaded on PalmPilots. Updated information is then downloaded every morning. As items fall below par levels, orders are automatically created and sent using PeopleSoft software to our purchasing department. Has your cath lab recently expanded in size and patient volume, or will it be in the near future? Our cath volumes have increased secondary to our EP and peripheral procedure numbers, which have grown significantly over the last two years. We also see many transfers from affiliated Henry Ford clinics and emergency rooms, including Henry Ford Fairlane, Sterling Heights, West Bloomfield, BiCounty Hospital, Wyandotte Hospital and Windsor, Ontario, Canada. Is your lab involved in clinical research? Yes. Combining over 30 years of experience in clinical trials research, Julianne Longlade, RN and Rachael Pangilinan, RN are experts in their field. They maintain and are responsible for Vascular surgeons have dedicated lab time on Tuesday and Thursday, and cardiologists, Monday, Wednesday and Friday. Our cardiology staff has been performing peripheral diagnostic and interventional procedures for over 6 years.

Table of Contents Feed for the Digital Edition of Cath Lab Digest - November 2007

Henry Ford Heart and Vascular Institute Treating Patients with Complex Vascular Disease with a Multi-Disciplinary Approach Improving Patient Compliance with Antiplatelet Medications Clinical Editor’s Corner Cath Lab Nurse/Tech Vascular Access and Closure Using the StarClose® Device The Clinical and Economic Impact of Measuring Fractional Flow Reserve FFR and Choosing an Optimal Revascularization Strategy Finally! The New Registered Cardiac Electrophysiology Specialist (RCES) Credential Use of a Mobile Lab to ‘Test the Waters’ at a Rural Hospital Remembering a Cardiac Cath Lab History ACVP• Membership Page What Do You Think? The Ten-Minute Interview with… Ernie Livingston, RN, BSN SICP* Chapter Updates Who’s in Charge? Working to Eliminate Bottlenecks: Florida Hospital’s Cardiac Cath Lab Achieves Greater Efficiency and Higher Satisfaction Preserving Left Ventricular Function during Percutaneous Coronary Intervention Ask the Clinical Instructor: A Q&A Column for Those New to the Cath Lab Making the Most of Your First Impression: Interviewing Tips and Techniques CEU Education Center Clinical & Industry News Meetings Calendar

Cath Lab Digest - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.